Beckley Psytech vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Beckley Psytech (now AtaiBeckley) achieved FDA Breakthrough Therapy Designation for BPL-003 (5-MeO-DMT nasal spray) for treatment-resistant depression in October 2025; Phase 3 trial initiation planned Q2 2026.
About
Beckley Psytech is a UK-based clinical-stage biotechnology company developing psychedelic-derived medicines for neuropsychiatric disorders, with a primary focus on treatment-resistant depression (TRD). Its lead asset, BPL-003, is an intranasal formulation of 5-MeO-DMT (mebufotenin benzoate) designed to deliver a controlled, short-duration psychedelic experience under medical supervision. In July 2025, Beckley Psytech and its partner atai Life Sciences reported positive topline results from a Phase 2b trial of BPL-003, with a single 8mg dose achieving a 12.1-point reduction on standardized depression scales at day 29 — a clinically meaningful outcome.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.